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H istorically,  neurodegenerative diseases were pathologically diagnosed only according to the 
anatomical distribution of tissue degeneration charac-
terized by neuronal loss with gliosis.  Later,  cytopatho-
logical features (e.g.,  neurofibrillary tangles (NFTs) and 
Lewy bodies,  etc. ) were regarded to be definitive bases 
in the diagnosis of degenerative diseases.  These inclu-
sions were first defined almost exclusively by morpho-
logical and histochemical features.  However,  along 
with the accumulation of biochemical findings,  it has 
been revealed that disease-specific proteins,  such as tau,  
α-synuclein,  and transactive response DNA-binding 
protein of 43 kDa (TDP-43),  are accumulated in dis-
tinctive neuronal and glial inclusions.  These proteins 
are often hyperphosphorylated,  which changes their 
conformations,  resulting in protein misfolding.  The 
protein misfolding can lead to protein aggregation,  
causing the impairment of cellular functions [1].  
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Neurodegenerative diseases in which tau accumulation plays a cardinal role in the pathogenic process are called 
tauopathies,  and when tau isoforms having four repeats of the microtubule binding sites,  four-repeat tau,  are 
selectively accumulated as pathological hallmarks,  the term four-repeat tauopathy is used.  The major four-re-
peat tauopathies are progressive supranuclear palsy (PSP),  corticobasal degeneration (CBD),  and argyrophilic 
grain disease (AGD).  Historically,  neuronal cytopathologies,  e.g.,  neurofibrillary tangles and ballooned neu-
rons,  were emphasized as characteristic lesions in PSP and CBD.  Now,  however,  astrocytic tau pathologies,  
i.e.,  tufted astrocytes (TAs) and astrocytic plaques (APs),  are considered to be highly disease-specific lesions.  
Although granular/fuzzy astrocytes (GFAs) frequently develop in the limbic system in AGD cases,  the specific-
ity is not conclusive yet.  Some AGD cases have a few TAs,  and to a lesser frequency,  a few APs in the frontal 
cortex and subcortical nuclei.  The number of astrocytic tau pathologies including TAs and GFAs increases with 
the progression of AGD.  In this paper,  histopathological features of astrocytic tau pathologies in PSP,  CBD,  
and AGD are first reviewed.  Then,  recent findings regarding the coexistence of these tauopathies are summa-
rized from a viewpoint of astrocytic tau pathologies.  Further biochemical and pathological studies focusing 
tau-positive astrocytic lesions may be useful to increase understanding of the pathological process in four-re-
peat tauopathies and to develop novel therapeutic strategies for patients with these diseases.
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Therefore,  the pathological diagnosis of most neurode-
generative diseases is now based on morphological,  
immunohistochemical,  and biochemical features asso-
ciated with disease-specific cytopathologies.
Neurodegenerative diseases in which the pathologi-
cal process is mainly associated with the abnormal 
accumulation of tau protein are called tauopathies.  Tau 
is a microtubule-associated protein that stabilizes 
microtubules [2].  Tau protein exists in six predominant 
isoforms by alternative mRNA splicing of exon 2,  exon 
3,  and exon 10 in a single gene,  MAPT [3 , 4].  Exon 10 
encodes the fourth microtubule-binding repeat.  Three 
isoforms have three repeats of the microtubule binding 
sites,  being called three-repeat tau (3R tau).  The 
remaining three isoforms have four repeats of the 
microtubule binding sites and are called four-repeat tau 
(4R tau) [5 , 6].  Tau immunoblotting of sarkosyl-insol-
uble brain extracts demonstrates 60 , 64,  and 68 kDa 
bands in AD cases,  while 60 and 64 kDa bands are 
revealed in Pick’s disease cases.  In PSP and CBD cases,  
64 and 68 kDa bands are revealed.  A doublet of 60 and 
64 kDa bands consists of 3R tau isoforms,  while a dou-
blet of 64 and 68 kDa bands consists of 4R tau isoforms.  
Therefore,  these findings suggest that the composition 
of filamentous tau is different between tauopathies.  
Indeed,  immunostaining using 3R tau- and 4R tau-spe-
cific antibodies demonstrates that NFTs in Alzheimer’s 
disease (AD) are composed of both 3R tau and 4R tau,  
while Pick bodies in Pick’s disease are basically com-
posed of 3R tau alone.  Several tauopathies in which 4R 
tau is selectively accumulated are called four-repeat 
tauopathies.  The major four-repeat tauopathies are pro-
gressive supranuclear palsy (PSP),  corticobasal degen-
eration (CBD),  and argyrophilic grain disease (AGD).  
Their cardinal cytopathological features are NFTs,  
threads,  coiled bodies,  and tufted astrocytes (TAs) in 
PSP; NFTs,  threads,  ballooned neurons,  and astro-
cytic plaques (APs) in CBD; and argyrophilic grains in 
AGD.  These lesions are labeled with 4R tau- but not 3R 
tau-specific antibodies.
In the first report of PSP by Steele et al.  in 1964 [7],  
the formation of NFTs in the subcortical nuclei was 
emphasized as a pathological feature.  In contrast,  they 
did not note any glial inclusions,  probably because only 
relatively insensitive conventional stains were available.  
About 30 years later,  morphologically distinct argyro-
philic astrocytic lesions,  so-called tufted astrocytes 
(TAs),  were discovered in PSP brains [8-11].  In the 
pathological diagnostic criteria proposed in 1994,  the 
presence of TAs was noted as a supportive feature of PSP 
[12].
Like PSP,  ballooned neurons were emphasized as 
characteristic histological changes in the first descrip-
tion of CBD by Rebeiz et al.  in 1968 [13],  although no 
glial inclusion was noted.  Now,  the occurrence of 
astrocytic plaques (APs) is considered to be highly dis-
ease specific and have diagnostic value in CBD [14].
Recently,  the classification of major tau-positive 
astrocytic lesions was proposed [15].  In the consensus 
paper,  TAs and APs are defined as astroglial lesions 
specific to PSP and CBD,  respectively.  Further,  globu-
lar astroglial inclusions and ramified astrocytes are clas-
sified as disease-specific lesions of globular glial tauop-
athy and Pick’s disease,  respectively.  On the other 
hand,  thorn-shaped astrocytes and granular/fuzzy 
astrocytes (GFAs) are considered to be astrocytic lesions 
that are not always specifically associated with degener-
ative diseases,  and they were named ‘age-related tau 
astrogliopathy’.  GFAs basically have morphological 
features identical to those of the bush-like astrocytes 
that were originally reported in AGD cases.  However,  
in a consensus paper,  it was noted that the specificity of 
GFAs was not established yet [15].
In this paper,  we first summarize the pathological 
features of tau-positive astrocytic lesions in the major 
four-repeat tauopathies,  i.e.,  PSP,  CBD,  and AGD.  
Then,  we show recent findings regarding the signifi-
cance of astrocytic tau pathologies in the evaluation of 
the coexistence of tauopathies and early pathological 
changes that are usually found incidentally.
Tau Astrogliopathy Specific to PSP
The occurrence of TAs is one of the cytopathological 
hallmarks of PSP,  in addition to 4R tau-positive NFTs,  
pretangles (diffuse or granular tau accumulations in 
neuronal cytoplasm with rare fibrillary formation),  
threads,  and coiled bodies [12].  TAs are clearly visual-
ized by the Gallyas method and tau immunohisto-
chemistry (Fig. 1A , 1B, 1C).  TAs immunopositive for 
glial fibrillary acidic protein (GFAP) are rare [16-18],  
and in general,  TAs are not found associated with 
infarcts or senile plaques [17].  Therefore,  it is consid-
ered that TAs may result from a degenerative process 
rather than a reactive change of astrocytes [17].  TAs are 
morphologically characterized by densely packed tau 
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accumulation in astrocytic processes.  Tau accumula-
tion is more prominent in the proximal portion than the 
distal portion of processes and cytoplasm of astrocytes 
[18].  This intracellular distribution of aggregated tau in 
TAs is in contrast to that in APs in CBD cases.  An 
astrocytic nucleus is often noted in the central portion 
of the radially arranged tau-positive processes.  TAs are 
often observed near vessel walls [19],  and radiating 
tau-positive processes are attached to them [18].  The 
distance between TAs and blood vessels is shorter than 
that between APs and blood vessels [19].
According to the pathological diagnostic criteria 
proposed in 1994 [12],  the diagnosis of PSP is primarily 
made according to the distribution and quantity of neu-
ronal tau accumulations,  such as NFTs,  pretangles,  
and threads.  Predilection sites of these lesions in PSP 
cases are the caudate nucleus,  putamen,  globus palli-
dus,  subthalamic nucleus,  oculomotor nucleus,  sub-
stantia nigra,  pontine nucleus,  inferior olivary nucleus,  
and dentate nucleus in the cerebellum [20-22].  In these 
criteria,  the presence of TAs is regarded as a supportive 
feature of PSP.  Predilection sites of TAs are not neces-
sarily identical to those of NFTs: TAs frequently occur 
in the primary motor cortex,  parietal cortex,  putamen,  
caudate nucleus,  globus pallidus,  substantia nigra,  red 
nucleus,  and inferior olivary nucleus [20-25].  It was 
reported that neuronal and glial cell pathologies are not 
spatially correlated [26].  These findings suggest that 
TAs do not always occur secondarily after NFTs are 
formed.
Immunohistochemically,  TAs are labeled with major 
anti-tau antibodies,  including AT8,  MC-1,  or Alz-50 
[10 , 16].  TAs are hardly labeled with anti-ubiquitin 
antibodies [21 , 27],  but often labeled with anti-p62 
antibodies [27].  4R tau is selectively accumulated in 
TAs as well as other tau pathologies including subcorti-
cal NFTs [28].
An ultrastructural study demonstrated that straight 
tubules forming loose bundles with a diameter of about 
15 nm were found in the astrocytic perikaryon [9].  In 
an ultrastructural study using filament-enriched frac-
tions extracted from the caudate nucleus and motor 
cortex in which the presence of many TAs was con-
firmed,  tau filaments were straight,  their contours were 
jagged,  and the mean width was 22 ± 5.5 nm [16].
Tau immunoblotting of the Sarkosyl-insoluble,  
urea-soluble fraction in the basal ganglia and brain stem 
in PSP cases demonstrates the doublet of 64 and 68 kDa 
bands and 33 kDa tau fragments [29 , 30].  Western 
blotting using filament-enriched fractions extracted 
from the caudate nucleus and motor cortex in which 
many TAs were present demonstrated that PHF-1 
revealed 68 and 64 kDa bands,  and E-10,  tau-1,  and 
tau 46 revealed 2-6 bands of 45-68 kDa [16].
Which anatomical sites are affected by PSP pathol-
ogy in the early stage of the course remains unclear.  In 
an early PSP case reported by Sakai et al.  [31],  TAs were 
found only in the caudate nucleus,  putamen,  globus 
pallidus,  and subthalamic nucleus,  while NFTs were 
widely distributed in the basal ganglia and brain stem 
nuclei.  In this case,  neuronal loss was noted only in the 
subthalamic nucleus and substantia nigra.  Thereafter,  
Nogami et al.  [32] explored early PSP pathology in 324 
consecutive autopsy cases.  They first screened for 4R 
tau-positive NFTs,  pretangles,  and TAs in the mid-
brain,  and selected 29 cases probably having early PSP 
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Fig. 1　 Tufted astrocytes in the frontal cortex in a case of progressive supranuclear palsy (PSP).  (A) Gallyas method,  (B) immunohisto-
chemistry using phosphorylation-dependent anti-tau antibody (AT8),  (C) tau immunohistochemistry using 4R tau-speciﬁc antibody (RD4).  
(B,C) The identical region is shown in mirror serial sections after reversal.  All scale bars＝50μm.  Figures used with permission from 
reference [39].
pathology but lacking other degenerative diseases.  Tau 
immunohistochemistry in the motor cortex,  opercular 
cortex,  basal ganglia,  and brain stem nuclei revealed 
TAs in the putamen in 8 cases (27.6% of 29 cases),  in 
the substantia nigra in 6 cases (20.7%),  and in the sub-
thalamic nucleus in 5 cases (17.2%).  Few TAs were 
noted in the other regions.  These findings suggest that 
sites where TAs initially occur may be the putamen,  
substantia nigra,  and subthalamic nucleus.
Tau Astrogliopathy Specific to CBD
The most important pathological hallmark of the 
diagnosis of CBD is the occurrence of APs (Fig. 2A ,  
2B , 2C).  In addition to APs,  CBD cases consistently 
have NFTs,  pretangles,  threads,  and ballooned neu-
rons in the subcortical nuclei and frontoparietal cortex.  
The occurrence of APs with typical morphology and 
distribution strongly supports the pathological diagno-
sis of CBD [15 , 20].  The presence of ballooned neurons 
was originally emphasized as an essential pathological 
feature of CBD [13].  However,  subsequent studies 
revealed that ballooned neurons can also develop in the 
limbic system in other degenerative diseases,  especially 
AGD [33].  The anatomical distribution of APs may not 
be necessarily identical to that of TAs in PSP.  Although 
both TAs and APs are frequent in the frontoparietal 
cortex and striatum,  TAs rather than APs tend to 
develop frequently in the globus pallidus,  subthalamic 
nucleus,  red nucleus,  and substantia nigra [21].  APs 
are clearly visualized by the Gallyas method and tau 
immunohistochemistry.  APs are labeled with anti-p62 
antibodies,  but hardly labeled with anti-ubiquitin anti-
bodies [21 , 27].  Like TAs in PSP,  some APs are GFAP-
positive [18].  Although APs are often observed near the 
vessels,  the distance between APs and vessel walls may 
be longer than that between TAs and vessel walls [19].  
Tau immunoblots demonstrated 64 and 68 kDa bands 
and low molecular weight tau fragments of 37 kDa 
[29 , 30].
A previous study demonstrated that TAs and APs did 
not coexist in 1 case when strict criteria were applied 
[8].  On the other hand,  Katsuse et al.  reported an 
autopsy case that had both TAs and APs,  and tau 
immunoblotting demonstrated 33 and 37 kDa bands as 
well as 64 and 68 kDa doublets [34].  However,  in this 
case the presence or absence of mutations in MAPT was 
not explored.  Tan et al.  reported 2 autopsy cases that 
had both APs and TAs.  These 2 cases lacked any MAPT 
mutation.  However,  tau immunoblotting demon-
strated only 64, 68,  and 37 kDa bands,  being consistent 
with the band pattern in CBD cases [35].  In cases that 
appear to have both CBD and PSP pathologies,  bio-
chemical and genetic analyses should be done because 
some reported cases with MAPT mutations show PSP- 
or CBD-like pathology [36].
Like PSP,  the available data regarding early lesions of 
CBD cases are very limited because it is difficult to 
accumulate early CBD cases.  Recently,  Ling et al.  
reported pathological features in 3 preclinical autopsy- 
confirmed CBD cases [37].  Compared with six 
advanced CBD cases,  tau pathology in the preclinical 
CBD cases was mild,  and APs were more prominent 
than neuronal tau accumulation,  suggesting that the 
formation of APs might precede that of NFTs and pre-
tangles.  Neurons in the substantia nigra were spared in 
number.  APs were noted in the anterior frontal white 
matter,  posterior frontal cortex,  parietal cortex,  amyg-
dala,  caudate nucleus,  putamen,  globus pallidus,  sub-
thalamic nucleus,  and substantia nigra.  These patho-
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Fig. 2　 Astrocytic plaques in the frontal cortex in a case of corticobasal degeneration (CBD).  (A) Gallyas method,  (B) AT8 immunohis-
tochemistry,  (C) RD4 immunohistochemistry.  All scale bars＝50μm.  Figures used with permission from reference [39].
logical features are consistent with those observed in our 
previously reported case having very early CBD pathol-
ogy (Fig. 3A-3L) [38].  In the present pathological crite-
ria of CBD,  neuronal loss in the substantia nigra is 
emphasized [20].  However,  given these findings,  it is 
likely that the neuronal loss in the site may be a charac-
teristic in advanced cases of CBD.
GFAs as an Age-related Tau Astrogliopathy
GFAs are tau-positive astrocytic lesions that are clas-
sified as a disease-nonspecific,  aging-related tau astro-
gliopathy (ARTAG),  which usually occurs in the gray 
matter rather than the white matter (Fig. 4) [15, 39, 40].  
In GFAs,  phosphorylated tau is densely accumulated in 
the perinuclear region of astrocytes,  and fine or granu-
lar tau accumulation in the astrocytic processes is radi-
ally distributed [15].  The Gallyas method occasionally 
demonstrates argyrophilia in the soma but not in the 
processes [15].  
The pathophysiological significance of GFAs remains 
unclear.  GFAs are immunohistochemically identical to 
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Fig. 3　 Early corticobasal degeneration (CBD) pathology with astrocytic plaques (APs).  (A-D) Astrocytic plaques in the superior frontal 
gyrus (A),  motor cortex (B),  caudate nucleus (C),  and putamen (D).  (E) A small number of tau-positive threads.  The putamen.  (G,I) A 
small number of NFTs and threads in the substantia nigra (G) and pontine nucleus (I).  (F,H) Unlike classic CBD cases,  neuronal loss with 
glial proliferation was not seen in the putamen (F) or substantia nigra (H).  (J) Argyrophilic grains.  The amygdala.  (K) A ballooned neuron 
and argyrophilic grains.  The amygdala.  (L) A ballooned neuron.  The amygdala.  (A,J) Gallyas-Braak silver stain,  (F,H,L) hematoxy-
lin-eosin stain,  (B,C,D,E,G, I ,K) AT8 immunohistochemistry.  Scale bars＝ (A ,C ,D ,E ,F ,G , I ,J ,K ,L) 50μm,  (B) 25μm,  (H) 100μ
m.  Figures used with permission from reference [38].
the bush-like astrocytes that were originally found in the 
limbic system in AGD cases [39-42].  In our recent 
study,  6 of 20 AGD cases (30.0%) had GFAs but no 
TAs,  and 5 (25.0%) had both GFAs and TAs [39, 40].  
That is,  GFAs were found in 55% of AGD cases [39, 40].  
However,  GFAs are not always specific to AGD [15].  
For example,  some PSP cases without AGD have not 
only TAs but also GFAs [39, 40].  Kovacs et al.  reported 
that elderly cases with mild to moderate NFTs and var-
ious quantities of neuritic plaques had GFAs in the fron-
tal,  temporal,  and cingulate cortices,  amygdala,  basal 
ganglia,  and brain stem nuclei [43-45].  In the consen-
sus paper on tau astrogliopathy,  it was recommended 
that in cases having GFAs,  underlying primary tauopa-
thies should be also documented [15].
The data of the distribution of GFAs are limited.  
Botez et al.  reported that GFAs (bush-like astrocytes in 
their paper) were found in the amygdala and entorhinal 
cortex,  but they did not examine any other regions [41].  
In our six AGD cases with GFAs but without TAs that 
did not meet the pathological criteria of other tauopa-
thies [39],  areas most frequently affected by GFAs were 
the putamen (66.7%),  followed by the caudate nucleus 
(50.0%),  frontal cortex (50.0%),  globus pallidus (33.3%),  
oculomotor nucleus (16.7%),  and pontine nucleus 
(16.7%).
Pathological Similarities of GFAs and TAs
Some AGD cases have not only GFAs but also a 
small number of TAs in the subcortical nuclei [42].  In 
our recent study,  5 of 20 AGD cases (25.0%) had TAs 
[39].  The morphological features of TAs in AGD cases 
were indistinguishable from those of TAs in PSP cases.  
Further,  AGD cases having TAs also had GFAs without 
exception.  Fig. 5 shows the distributions of TAs (red 
bars) and GFAs (purple bars) in AGD cases.  These find-
ings suggest that both TAs and GFAs preferentially 
developed in the putamen,  caudate nucleus,  and supe-
rior frontal cortex in AGD cases [39 , 40].  Further,  the 
predilection sites of TAs in PSP cases (green bars) were 
consistent with those of GFAs and TAs in AGD cases 
[39 , 40].
On double staining by AT8 immunohistochemistry 
and the Gallyas method,  a small number of fine Gallyas-
positive glial thread-like structures are observed in the 
distal portion of some GFAs in AGD cases (Fig. 6) 
[39 , 40].  In PSP cases without AGD also,  GFAs with 
and without a varying quantity of Gallyas-positive glial 
threads were found [39 , 40].  These findings support the 
possibility that at least some GFAs can evolve into 
Gallyas-positive TAs.
Increase of Astrocytic Tau Pathologies 
Associated with Progression of AGD
In our previous study,  the number of tau-positive 
astrocytic lesions (including GFAs and TAs) increased 
with the progression of AGD (Fig. 7) [39].  Likewise,  
the quantity of TAs stained with the Gallyas method 
increased with the progression of AGD (Fig. 8) [39 , 40].  
Interestingly,  in this study,  abnormal neuronal tau 
accumulation in the subcortical nuclei also increased 
with the progression of AGD [39].  Several other studies 
also demonstrated that some AGD cases had neuronal 
tau accumulation (i.e.,  NFTs and pretangles) in the sub-
cortical nuclei [42 , 46-50].  These findings led us to 
consider that the progression of AGD may be associated 
with the formation of astrocytic tau pathologies and tau 
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Fig. 4　 Granular/fuzzy astrocytes (GFAs) in argyrophilic grain disease (AGD) cases.  All scale bars＝50μm.  Figures used with permis-
sion from reference [39].
accumulation in neurons in the subcortical nuclei.
Coexistence of AGD with PSP and CBD:  
Implications of Astrocytic Tau Pathologies
PSP cases often have coexisting AGD at frequencies 
ranging from 18.8% [28] to 80% [46].  On the other 
hand,  as noted above,  a small number of TAs is fre-
quently found in AGD cases,  which comprised 25.0% 
in our series [39].  It is also known that AGD frequently 
coexists with CBD pathology at a frequency ranging 
from 41.2% [51] to 100% [46 , 52 , 53],  being higher 
than those in PSP.  In contrast,  the occurrence of APs in 
AGD cases may be rare,  and the frequency was only 
5.0% in our series [39].  Why the frequency of APs is far 
lower than that of TAs in AGD cases remains unclear.  It 
might be explained by the possible low frequency of 
CBD in general populations.  It is also unclear why the 
frequency of APs in AGD cases is low (5%),  although 
the frequency of AGD in CBD cases was reported to be 
very high (41% to 100%).  These findings led us to con-
sider that argyrophilic grains may frequently occur 
parallel to the progression of CBD pathology,  and that 
it may be rare that CBD pathology is secondarily formed 
after the progression of AGD.
Conclusions
A recently proposed classification of tau-positive 
astrocytic lesions may provide a novel viewpoint from 
which to examine the pathophysiology of four-repeat 
tauopathies.  Several findings focusing on astrocytic tau 
pathologies support the possibility that at least some,  
although not all,  four-repeat tauopathies share a com-
mon pathophysiological background.  Further bio-
chemical and pathological studies focusing astrocytic 
lesions may be useful to increase understanding of the 
pathological process in four-repeat tauopathies and to 
develop novel therapeutic strategies for patients with 
these diseases.
June 2018 Tau Astrogliopathy and Neurodegeneration 217
Fig. 5　 The predilection sites of Gallyas-positive tau-positive tufted astrocytes (TAs) in argyrophilic grain disease (AGD) cases (n＝5),  
Gallyas-negative tau-positive granular/fuzzy astrocytes (GFAs) in AGD cases (n＝6),  and TAs in PSP cases (n＝9).  The proportions of 
cases having these astrocytic lesions by anatomical region are indicated.  The predilection sites of TAs (red) and GFAs (purple) in AGD 
cases are similar to that of TAs in PSP cases (green).  A graph produced using the data from Ikeda et al.  [39].  A graph used with permis-
sion from reference [40].
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Fig. 6　 Tufted astrocytes (TAs) and granular/fuzzy astrocytes (GFAs) in AGD and PSP cases.  Double staining of AT8 immunohisto-
chemistry and Gallyas method.  (A,B,C,D) Astrocytic tau pathology in the superior frontal cortex in an AGD case having both GFAs (A) 
and TAs (B,C,D).  The proportion of Gallyas-positive structures varied between lesions.  A small number of ﬁne Gallyas-positive glial 
threads were often observed in the distal portion of astrocytic lesions.  (E,F,G,H) GFAs and TAs in the putamen in a PSP case.  (E) 
GFAs had ﬁne granular tau accumulations that were radially arranged.  It is hard to morphologically distinguish GFAs in PSP cases (E) from 
GFAs in AGD cases (A).  (F) When the number of Gallyas-positive thread-like structures was small,  they were often found in the distal 
portion of each astrocytic lesion.  (G) The lesion on the right (GFA) lacks a Gallyas-positive structure,  while the one on the left (TA) has 
Gallyas-positive thread-like structures.  (H) A right-hand lesion (TA) has Gallyas-positive thread-like structures,  while the left-hand one 
(GFA) lacks Gallyas-positive structures.  The peroxidase labeling was visualized with DAB (B,D,F) or Vector NovaRED (A,C,E,G,H).  
All scale bars＝20μm.  Figures used with permission from reference [39].
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Fig. 7　 Quantity of tau (AT8)-positive astrocytic lesions by AGD stage in AGD cases.  The number of astrocytic lesions (TAs and GFAs) 
is shown on the vertical axis: stage 0,  no lesion; stage 1,  one TA in the anatomical region; stage 2,  two to four TAs in the anatomical 
lesion but less than one TA per ×200 visual ﬁeld; stage 3,  one TA per ×200 visual ﬁeld; stage 4,  2 to 10 TAs per ×200 visual ﬁeld;  
stage 5,  11 to 20 TAs per ×200 visual ﬁeld; stage 6,  over 20 TAs per ×200 visual ﬁeld.  In all regions,  the number of tau-positive astro-
cytic lesions was sequentially increased with the progression of AGD stage.  In the caudate nucleus,  oculomotor nucleus,  and inferior oli-
vary nucleus,  the diﬀerences between the quantities of astrocytic lesions in diﬀerent AGD stages reached statistical signiﬁcance.  
AGD1: Saito stage I; AGD2: Saito sage II; AGD3: Saito stage III.  Kruskal-Wallis and Steel-Dwass tests; ＊p＜0.05; ＊＊p＜0.01.  
Graphs used with permission from reference [39].
Fig. 8　 The relationship between the quantity of Gallyas-positive TAs and the severity of argyrophilic grains (Saito stage) in AGD cases.  
The number of TAs is shown on the vertical axis: stage 0,  no lesion; stage 1,  one TA in the anatomical region; stage 2,  two to four TAs 
in the anatomical lesion but less than one TA per ×200 visual ﬁeld; stage 3,  one TA per ×200 visual ﬁeld; stage 4,  2 to 10 TAs per 
×200 visual ﬁeld; stage 5,  11 to 20 TAs per ×200 visual ﬁeld; stage 6,  over 20 TAs per ×200 visual ﬁeld.  AGD1: Saito stage I;  
AGD2: Saito sage II; AGD3: Saito stage III.  Kruskal-Wallis and Steel-Dwass tests; ＊p＜0.05; ＊＊p＜0.01.  The quantity of TAs tends to 
be sequentially increased with the progression of AGD,  and a signiﬁcant diﬀerence between AGD stages was found in the frontal cortex.  
Graphs produced using the data in our previous study [39].  Graphs used with permission from reference [40].
Acknowledgments.　We thank Mses. Y. Matsuo and M.  Onbe for their 
technical assistance.  This work was supported by Grants-in-Aid for 
Scientific Research (C) from the Japanese Ministry of Education,  Culture,  
Sports,  Science and Technology (MEXT KAKENHI Grant No. 15K09867),  
Grants-in-Aid from the Research Committee of CNS Degenerative Diseases 
and Research on Dementia from the Ministry of Health,  Labour and 
Welfare of Japan (H29-Nanchi-Ippan-033),  an Intramural Research Grant 
for Neurological and Psychiatric Disorders from National Center of 
Neurology and Psychiatry (NCNP) (27-6-2, 30-8),  grants from the Strategic 
Research Program for Brain Sciences from Japan Agency for Medical 
Research and Development (AMED,  JP17dm0107109,  JP17kk0205009),  
and grants from Zikei Institute of Psychiatry.
References
 1. Aguzzi A and Kana V: Protein aggregation in neurodegeneration;  
in Neurodegeneration: the Molecular Pathology of Dementia and 
Movement Disorders,  Dickson DW and Weller RO eds,  Second 
Ed,  Wiley-Blackwell Press,  Oxford (2011) pp13-17.
 2. Goedert M: Introduction of the tauopathies; in Neurodegeneration:  
the Molecular Pathology of Dementia and Movement Disorders,  
Dickson DW and Weller RO eds,  Second Ed,  Wiley-Blackwell 
Press,  Oxford (2011) pp105-109.
 3. Goedert M,  Spillantini MG,  Jakes R,  Rutherford D and Crowther 
RA: Multiple isoforms of human microtubule-associated protein 
tau: sequences and localization in neuroﬁbrillary tangles of 
Alzheimerʼs disease.  Neuron (1989) 3: 519-526.
 4. Andreadis A,  Brown WM and Kosik KS: Structure and novel exons 
of the human tau gene.  Biochemistry (1992) 31: 10626-10633.
 5. Ennulat DJ,  Liem RK,  Hashim GA and Shelanski ML: Two sepa-
rate 18-amino acid domains of tau promote the polymerization of 
tubulin.  J Biol Chem (1989) 264: 5327-5330.
 6. Lee G,  Neve RL and Kosik KS: The microtubule binding domain 
of tau protein.  Neuron (1989) 2: 1615-1624.
 7. Steele JC,  Richardson JC and Olszewski J: Progressive supranu-
clear palsy.  A heterogeneous degeneration involving the brain 
stem,  basal ganglia and cerebellum with vertical gaze and 
pseudobulbar palsy,  nuchal dystonia and dementia.  Arch Neurol 
(1964) 10: 333-359.
 8. Komori T,  Arai N,  Oda M,  Nakayama H,  Mori H,  Yagishita S,  
Takahashi T,  Amano N,  Murayama S,  Murakami S,  Shibata N,  
Kobayashi M,  Sasaki S and Iwata M: Astrocytic plaques and tufts 
of abnormal ﬁbers do not coexist in corticobasal degeneration and 
progressive supranuclear palsy.  Acta Neuropathol (1998) 96: 401-
408.
 9. Nishimura M,  Namba Y,  Ikeda K and Oda M: Glial ﬁbrillary tan-
gles with straight tubules in the brains of patients with progressive 
supranuclear palsy.  Neurosci Lett (1992) 143: 35-38.
10. Nishimura T,  Ikeda K,  Akiyama H,  Kondo H,  Kato M,  Li F,  Iseki 
E and Kosaka K: Immunohistochemical investigation of tau-posi-
tive structures in the cerebral cortex of patients with progressive 
supranuclear palsy.  Neurosci Lett (1995) 201: 123-126.
11. Yamada T,  McGeer PL and McGeer EG: Appearance of paired 
nucleated,  Tau-positive glia in patients with progressive supranu-
clear palsy brain tissue.  Neurosci Lett (1992) 135: 99-102.
12. Hauw JJ,  Daniel SE,  Dickson D,  Horoupian DS,  Jellinger K,  
Lantos PL,  McKee A,  Tabaton M and Litvan I: Preliminary NINDS 
neuropathologic criteria for Steele-Richardson-Olszewski syndrome 
(progressive supranuclear palsy).  Neurology (1994) 44: 2015-2019.
13. Rebeiz JJ,  Kolodny EH and Richardson EP Jr.: Corticodentatonigral 
degeneration with neuronal achromasia.  Arch Neurol (1968) 18:  
20-33.
14. Feany MB and Dickson DW: Widespread cytoskeletal pathology 
characterizes corticobasal degeneration.  Am J Pathol (1995) 146:  
1388-1396.
15. Kovacs GG,  Ferrer I,  Grinberg LT,  Alafuzoﬀ I,  Attems J,  Budka H,  
Cairns NJ,  Crary JF,  Duyckaerts C,  Ghetti B,  Halliday GM,  
Ironside JW,  Love S,  Mackenzie IR,  Munoz DG,  Murray ME,  
Nelson PT,  Takahashi H,  Trojanowski JQ,  Ansorge O,  Arzberger T,  
Baborie A,  Beach TG,  Bieniek KF,  Bigio EH,  Bodi I,  Dugger BN,  
Feany M,  Gelpi E,  Gentleman SM,  Giaccone G,  Hatanpaa KJ,  
Heale R,  Hof PR,  Hofer M,  Hortobágyi T,  Jellinger K,  Jicha GA,  
Ince P,  Koﬂer J,  Kövari E,  Kril JJ,  Mann DM,  Matej R,  McKee 
AC,  McLean C,  Milenkovic I,  Montine TJ,  Murayama S,  Lee EB,  
Rahimi J,  Rodriguez RD,  Rozemüller A,  Schneider JA,  Schultz C,  
Seeley W,  Seilhean D,  Smith C,  Tagliavini F,  Takao M,  Thal DR,  
Toledo JB,  Tolnay M,  Troncoso JC,  Vinters HV,  Weis S,  
Wharton SB,  White CL 3rd,  Wisniewski T,  Woulfe JM,  Yamada M 
and Dickson DW: Aging-related tau astrogliopathy (ARTAG):  
harmonized evaluation strategy.  Acta Neuropathol (2016) 131: 87-
102.
16. Takahashi M,  Weidenheim KM,  Dickson DW and Ksiezak-Reding H:  
Morphological and biochemical correlations of abnormal tau ﬁla-
ments in progressive supranuclear palsy.  J Neuropathol Exp Neurol 
(2002) 61: 33-45.
17. Togo T and Dickson DW: Tau accumulation in astrocytes in pro-
gressive supranuclear palsy is a degenerative rather than a reac-
tive process.  Acta Neuropathol (2002) 104: 398-402.
18. Yoshida M: Astrocytic inclusions in progressive supranuclear palsy 
and corticobasal degeneration.  Neuropathology (2014) 34: 555-
570.
19. Shibuya K,  Yagishita S,  Nakamura A and Uchihara T: Perivascular 
orientation of astrocytic plaques and tuft-shaped astrocytes.  Brain 
Res (2011) 1404: 50-54.
20. Dickson DW,  Bergeron C,  Chin SS,  Duyckaerts C,  Horoupian D,  
Ikeda K,  Jellinger K,  Lantos PL,  Lippa CF,  Mirra SS,  Tabaton M,  
Vonsattel JP,  Wakabayashi K and Litvan I; Oﬃce of Rare Diseases 
of the National Institutes of Health: Oﬃce of Rare Diseases neuro-
pathologic criteria for corticobasal degeneration.  J Neuropathol 
Exp Neurol (2002) 61: 935-946.
21. Dickson DW,  Hauw JJ,  Agid Y and Litvan I: Progressive supranu-
clear palsy and corticobasal degeneration; in Neurodegeneration:  
the Molecular Pathology of Dementia and Movement Disorders,  
Dickson DW and Weller RO eds,  Second Ed,  Wiley-Blackwell 
Press,  Oxford (2011) pp135-155.
22. Armstrong RA,  Lantos PL and Cairns NJ: Progressive supranu-
clear palsy (PSP): a quantitative study of the pathological changes 
in cortical and subcortical regions of eight cases.  J Neural Transm 
(Vienna) (2007) 114: 1569-1577.
23. Hattori M,  Hashizume Y,  Yoshida M,  Iwasaki Y,  Hishikawa N,  
Ueda R and Ojika K: Distribution of astrocytic plaques in the corti-
cobasal degeneration brain and comparison with tuft-shaped astro-
cytes in the progressive supranuclear palsy brain.  Acta Neuropathol 
(2003) 106: 143-149.
24. Iwasaki Y,  Yoshida M,  Hattori M,  Goto A,  Aiba I,  Hashizume Y 
and Sobue G: Distribution of tuft-shaped astrocytes in the cerebral 
cortex in progressive supranuclear palsy.  Acta Neuropathol (2004) 
108: 399-405.
25. Ito K,  Arai K,  Yoshiyama Y,  Kashiwado K,  Sakakibara Y and 
Hattori T: Astrocytic tau pathology positively correlates with neu-
roﬁbrillary tangle density in progressive supranuclear palsy.  Acta 
220 Ikeda et al. Acta Med.  Okayama　Vol.  72,  No.  3
Neuropathol (2008) 115: 623-628.
26. Armstrong RA and Cairns NJ: Spatial patterns of the tau pathology 
in progressive supranuclear palsy.  Neurol Sci (2013) 34: 337-344.
27. Kuusisto E,  Kauppinen T and Alafuzoﬀ I: Use of p62/SQSTM1 
antibodies for neuropathological diagnosis.  Neuropathol Appl 
Neurobiol (2008) 34: 169-180.
28. Togo T,  Sahara N,  Yen SH,  Cookson N,  Ishizawa T,  Hutton M,  
de Silva R,  Lees A and Dickson DW: Argyrophilic grain disease is 
a sporadic 4-repeat tauopathy.  J Neuropathol Exp Neurol (2002) 
61: 547-556.
29. Arai T,  Ikeda K,  Akiyama H,  Shikamoto Y,  Tsuchiya K,  Yagishita 
S,  Beach T,  Rogers J,  Schwab C and McGeer PL: Distinct iso-
forms of tau aggregated in neurons and glial cells in brains of 
patients with Pickʼs disease,  corticobasal degeneration and pro-
gressive supranuclear palsy.  Acta Neuropathol (2001) 101: 167-
173.
30. Arai T,  Ikeda K,  Akiyama H,  Nonaka T,  Hasegawa M,  Ishiguro K,  
Iritani S,  Tsuchiya K,  Iseki E,  Yagishita S,  Oda T and Mochizuki 
A: Identiﬁcation of amino-terminally cleaved tau fragments that 
distinguish progressive supranuclear palsy from corticobasal 
degeneration.  Ann Neurol (2004) 55: 72-79.
31. Sakai K and Yamada M: Early-stage progressive supranuclear 
palsy with degenerative lesions conﬁned to the subthalamic 
nucleus and substantia nigra.  Neuropathology (2011) 31: 77-81.
32. Nogami A,  Yamazaki M,  Saito Y,  Hatsuta H,  Sakiyama Y,  Takao 
M,  Kimura K and Murayama S: Early stage of progressive supra-
nuclear palsy: A neuropathological study of 324 consecutive 
autopsy cases.  J Nippon Med Sch (2015) 82: 266-273.
33. Togo T and Dickson DW: Ballooned neurons in progressive supra-
nuclear palsy are usually due to concurrent argyrophilic grain dis-
ease.  Acta Neuropathol (2002) 104: 53-56.
34. Katsuse O,  Iseki E,  Arai T,  Akiyama H,  Togo T,  Uchikado H,  
Kato M,  de Silva R,  Lees A and Kosaka K: 4-Repeat tauopathy 
sharing pathological and biochemical features of corticobasal 
degeneration and progressive supranuclear palsy.  Acta Neuropathol 
(2003) 106: 251-260.
35. Tan CF,  Piao YS,  Kakita A,  Yamada M,  Takano H,  Tanaka M,  
Mano A,  Makino K,  Nishizawa M,  Wakabayashi K and Takahashi 
H: Frontotemporal dementia with co-occurrence of astrocytic 
plaques and tufted astrocytes,  and severe degeneration of the 
cerebral white matter: a variant of corticobasal degeneration? Acta 
Neuropathol (2005) 109: 329-338.
36. Tsuboi Y: Neuropathology of familial tauopathy.  Neuropathology 
(2006) 26: 471-474.
37. Ling H,  Kovacs GG,  Vonsattel JP,  Davey K,  Mok KY,  Hardy J,  
Morris HR,  Warner TT,  Holton JL and Revesz T: Astrogliopathy 
predominates the earliest stage of corticobasal degeneration 
pathology.  Brain (2016) 139: 3237-3252.
38. Nagao S,  Yokota O,  Ikeda C,  Takeda N,  Ishizu H,  Kuroda S,  
Sudo K,  Terada S,  Murayama S and Uchitomi Y: Argyrophilic 
grain disease as a neurodegenerative substrate in late-onset 
schizophrenia and delusional disorders.  Eur Arch Psychiatry Clin 
Neurosci (2014) 264: 317-331.
39. Ikeda C,  Yokota O,  Nagao S,  Ishizu H,  Oshima E,  Hasegawa M,  
Okahisa Y,  Terada S and Yamada N: The relationship between 
development of neuronal and astrocytic tau pathologies in subcorti-
cal nuclei and progression of argyrophilic grain disease.  Brain 
Pathol (2016) 26: 488-505.
40. Yokota O,  Miki T,  Ikeda C,  Nagao S,  Takenoshita S,  Ishizu H,  
Haraguchi T,  Kuroda S,  Terada S and Yamada N: Neuropatho-
logical comorbidity associated with argyrophilic grain disease.  
Neuropathology (2018) 38: 82-97.
41. Botez G,  Probst A,  Ipsen S and Tolnay M: Astrocytes expressing 
hyperphosphorylated tau protein without glial ﬁbrillary tangles in 
argyrophilic grain disease.  Acta Neuropathol (1999) 98: 251-256.
42. Santpere G and Ferrer I: Delineation of early changes in cases 
with progressive supranuclear palsy-like pathology.  Astrocytes in 
striatum are primary targets of tau phosphorylation and GFAP oxi-
dation.  Brain Pathol (2009) 19: 177-187.
43. Kovacs GG,  Molnár K,  László L,  Ströbel T,  Botond G,  
Hönigschnabl S,  Reiner-Concin A,  Palkovits M,  Fischer P and 
Budka H: A peculiar constellation of tau pathology deﬁnes a sub-
set of dementia in the elderly.  Acta Neuropathol (2011) 122: 205-
222.
44. Ferrer I,  López-González I,  Carmona M,  Arregui L,  Dalfó E,  
Torrejón-Escribano B,  Diehl R and Kovacs GG: Glial and neuronal 
tau pathology in tauopathies: characterization of disease-speciﬁc 
phenotypes and tau pathology progression.  J Neuropathol Exp 
Neurol (2014) 73: 81-97.
45. Kovacs GG: Invited review: Neuropathology of tauopathies: prin-
ciples and practice.  Neuropathol Appl Neurobiol (2015) 41: 3-23.
46. Martinez-Lage P and Munoz DG: Prevalence and disease associa-
tions of argyrophilic grains of Braak.  J Neuropathol Exp Neurol 
(1997) 56: 157-164.
47. Mattila P,  Togo T and Dickson DW: The subthalamic nucleus has 
neuroﬁbrillary tangles in argyrophilic grain disease and advanced 
Alzheimerʼs disease.  Neurosci Lett (2002) 320: 81-85.
48. Masliah E,  Hansen LA,  Quijada S,  DeTeresa R,  Alford M,  Kauss 
J and Terry R: Late onset dementia with argyrophilic grains and 
subcortical tangles or atypical progressive supranuclear palsy? Ann 
Neurol (1991) 29: 389-396.
49. Ishihara K,  Araki S,  Ihori N,  Shiota J,  Kawamura M,  Yoshida M,  
Hashizume Y and Nakano I: Argyrophilic grain disease presenting 
with frontotemporal dementia: a neuropsychological and pathologi-
cal study of an autopsied case with presenile onset.  Neuropathology 
(2005) 25: 165-170.
50. Itagaki S,  McGeer PL,  Akiyama H,  Beattie BL,  Walker DG,  
Moore GR and McGeer EG: A case of adult-onset dementia with 
argyrophilic grains.  Ann Neurol (1989) 26: 685-659.
51. Ding ZT,  Wang Y,  Jiang YP,  Yoshida M,  Mimuro M,  Inagaki T,  
Iwase T and Hashizume Y: Argyrophilic grain disease: frequency 
and neuropathology in centenarians.  Acta Neuropathol (2006) 
111: 320-328.
52. Tatsumi S,  Mimuro M,  Iwasaki Y,  Takahashi R,  Kakita A,  
Takahashi H and Yoshida M: Argyrophilic grains are reliable dis-
ease-speciﬁc features of corticobasal degeneration.  J Neuropathol 
Exp Neurol (2014) 73: 30-38.
53. Ikeda C,  Yokota O,  Nagao S,  Ishizu H,  Morisada Y,  Terada S,  
Nakashima Y,  Akiyama H and Uchitomi Y: Corticobasal degener-
ation initially developing motor versus non-motor symptoms: a 
comparative clinicopathological study.  Psychogeriatrics (2014) 14:  
152-164.
June 2018 Tau Astrogliopathy and Neurodegeneration 221
